Recombinant MAGT1 facilitates Mg²⁺ uptake in T cells, maintaining cytoplasmic Mg²⁺ levels critical for immune activation. Deficiency impairs CD8⁺ T-cell responses to viral infections (e.g., Epstein-Barr virus) .
MAGT1 serves as an accessory subunit of the oligosaccharyltransferase (OST) complex, enabling posttranslational glycosylation of cysteine-proximal sites in glycoproteins . This activity is Mg²⁺-sensitive and partially overlaps with its paralog TUSC3 .
MAGT1-deficient mice exhibit accelerated arterial thrombosis, hyperactive platelets, and increased TRPC6-dependent calcium influx .
In humans, mutations cause XMEN syndrome (X-linked immunodeficiency with Mg²⁺ defect), characterized by chronic EBV infections and lymphoproliferative disorders .
Overexpression in colorectal cancer (CRC) correlates with advanced tumor stages, metastasis, and chemotherapy resistance .
MAGT1 knockdown reduces CRC cell proliferation and migration in vitro .
MAGT1 loss disrupts glycosylation of immune receptors (e.g., CD28) and NKG2D, impairing antiviral responses .
Mg²⁺ supplementation partially restores glycosylation in MAGT1-deficient cells .
Gene Therapy: Restoration of MAGT1 in hematopoietic stem cells could correct immune defects in XMEN patients .
Drug Targets: TRPC6 inhibitors normalize platelet hyperactivity in MAGT1-deficient models .
Antibody Production: MAGT1-specific antibodies (e.g., Proteintech 17430-1-AP) are validated for Western blot, IHC, and IF .
CRISPR Models: MAGT1-KO cell lines elucidate its roles in Mg²⁺ homeostasis and glycosylation .
Solubility: MAGT1’s transmembrane domains require detergent-based extraction for recombinant expression .
Glycoform Variability: Posttranslational modifications affect molecular weight (38–47 kDa), complicating purification .